Glatiramer Acetate

Summary

Glatiramer Acetate (CHEMBL1201507) is an approved small molecule (ATC L03AX13); indicated across 11 conditions including neoplasm and multiple sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L03AX13
• Indications: 11 conditions
• Clinical trials: 44

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201507
Name	Glatiramer Acetate
Type	Small molecule
Max phase	4
ATC	L03AX13

Also known as: COP-1, Copaxone, COPOLYMER-1, Glatiramer acetate, Glatopa, GLATIRAMER ACETATE, glatiramer acetate

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
multiple sclerosis	4	MONDO:0005301	MONDO:0005301

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
relapsing-remitting multiple sclerosis	3	MONDO:0005314	EFO:0003929
optic neuritis	3	MONDO:0005885	EFO:0007405
primary angle-closure glaucoma	3	MONDO:0001868	EFO:1001506
Crohn disease	2	MONDO:0005011	EFO:0000384
chronic progressive multiple sclerosis	2	MONDO:0005284	EFO:0003840
secondary progressive multiple sclerosis	2	MONDO:0000450	EFO:0008522
macular degeneration	2	MONDO:0003004	EFO:0009606
amyotrophic lateral sclerosis	2	MONDO:0004976	MONDO:0004976
Rett syndrome	2	MONDO:0010726	MONDO:0010726

Clinical trials

Total trials: 44.

Phase distribution

Phase	Trials
Not specified	12
PHASE3	11
PHASE2	11
PHASE4	7
PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00176592	PHASE4	COMPLETED	Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
NCT00202995	PHASE4	TERMINATED	Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
NCT00203021	PHASE4	COMPLETED	Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
NCT00203047	PHASE4	TERMINATED	Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
NCT00239993	PHASE4	COMPLETED	A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
NCT00267319	PHASE4	COMPLETED	FOCUS Fatigue Outcome in Copaxone USers
NCT00910598	PHASE4	UNKNOWN	Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
NCT07189325	PHASE3	NOT_YET_RECRUITING	A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT00099502	PHASE3	COMPLETED	BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
NCT00211887	PHASE3	COMPLETED	Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
NCT00451451	PHASE3	COMPLETED	Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
NCT00856635	PHASE3	COMPLETED	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
NCT00947752	PHASE3	COMPLETED	Safety of New Formulation of Glatiramer Acetate
NCT01058005	PHASE3	TERMINATED	Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
NCT01578785	PHASE3	TERMINATED	An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01633112	PHASE3	TERMINATED	MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
NCT01936129	PHASE3	UNKNOWN	Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure
NCT03315923	PHASE2/PHASE3	COMPLETED	Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients
NCT03368664	PHASE3	TERMINATED	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
NCT00203099	PHASE2	COMPLETED	Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
NCT00326625	PHASE2	COMPLETED	Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
NCT00451204	PHASE2	COMPLETED	A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
NCT00731172	PHASE2	UNKNOWN	A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn’s Disease
NCT00939549	PHASE2	WITHDRAWN	High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis
NCT01071083	PHASE2	COMPLETED	Treatment Interruption of Natalizumab
NCT01569451	PHASE2	COMPLETED	Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
NCT01963611	PHASE2	TERMINATED	Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
NCT02153723	PHASE2	COMPLETED	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
NCT04079088	PHASE2	WITHDRAWN	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
NCT06003972	PHASE2	COMPLETED	Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure
NCT00541333	PHASE1	SUSPENDED	Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
NCT03982212	PHASE1	UNKNOWN	A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
NCT03500328	Not specified	ACTIVE_NOT_RECRUITING	Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
NCT05344469	Not specified	RECRUITING	A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
NCT05688436	Not specified	RECRUITING	A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
NCT00039988	Not specified	COMPLETED	Treatment of Multiple Sclerosis With Copaxone and Albuterol
NCT00331747	Not specified	UNKNOWN	Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
NCT00398528	Not specified	TERMINATED	An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis
NCT00490906	Not specified	COMPLETED	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
NCT00819195	Not specified	COMPLETED	Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
NCT00937157	Not specified	COMPLETED	Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
NCT03209479	Not specified	COMPLETED	Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis
NCT04928313	Not specified	COMPLETED	Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
NCT05762003	Not specified	COMPLETED	Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).